Skip to main content

Center for Vaccine Development (CVD)

CVD Overview


Life-saving immunizations are one of seven great achievements in pediatric research in the past 40 years (Cheng, Monteiro et al. 2016).

Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. The faculty and global staff includes molecular biologists, microbiologists, immunologists, internists, pediatricians, epidemiologists, malariologists, and biostatisticians.

Vaccines are a powerful tool to fight infectious diseases worldwide. For over 40 years, the CVD at the University of Maryland School of Medicine (UM SOM) in Baltimore, MD has worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of vaccinology from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments.

While the main research thrust of basic research at the CVD has historically focused on bacterial enteric pathogens, rotavirus, and malaria, it has also worked more broadly on bacterial diseases, parasitic diseases, viral diseases, novel delivery systems, public health, and vaccine policy.

Resources

History


Leadership

Dr. Neuzil brings over two decades of experience in infectious diseases and vaccine science, policy, and introduction. She’s led or been involved in pivotal vaccine trials that have influenced vaccine policy worldwide. A strong advocate for translating research results into vaccine policies, she was a key driver in the many changes in the influenza policy in the United States. Internationally, her research helped shape rotavirus vaccine policy. She is an expert on influenza, rotavirus, and RSV as well as in maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings.


Mission

Harness the power of vaccines to prevent disease and save lives in the most vulnerable populations.

Studies to support meeting our mission:

  • Disease burden/epidemiology to prioritize the most needed vaccines
  • Molecular pathogenesis of disease-causing infections
  • Antigen discovery for the design of effective vaccines
  • Pre-clinical vaccine development to make vaccines that are safe and effective in humans
  • Phase I, II, III, IV vaccine trials to evaluate the safety and efficacy in humans
  • Human challenge trials to understand the infectious process and measure vaccine efficacy
  • Immune correlates of protection to understand how best to stimulate immunity
  • Vaccine policy to introduce effective vaccines into vulnerable populations
  • Train the next generation of vaccinologists

Volunteer Opportunities

Give to this Department


Connect with Us:


Kathleen Neuzil, MD, MPH
CVD Director & Deputy Director of the IGH


CVD NEWS

Kirsten Lyke, MD, awarded Division of Geographic Medicine Faculty Teacher of the Year, 8 June 2017.

Kirsten Lyke, MD, awarded the Department of Medicine Basic Science Publication of the Year for her publication Attenuated PfSPZ Vaccine Induces Strain-transcending T Cells and Durable Protection Against Heterologous Controlled Human Malaria Infection, 8 June 2017.

Pneumonia Etiology Child Health Research Methods and Preparatory Results Published: Largest Pneumonia Study Conducted in 30 Years, 7 June 2017.

Karen Kotloff, MD, Samba Sow, MD, MS, and Milagritos Tapia, MD were among the co-authors on many publications from the Pneumonia Etiology Research for Child Health (PERCH) project published in a 23-paper supplement in Clinical Infectious Diseases, 7 June 2017.

Kathleen Neuzil, MD, MPH, talks about the effectiveness of the influenza vaccine in the video Vaccine Significantly Reduces Risk for Influenza-related Death in Children, 5 June 2017.

Karen Kotloff, MD, was amogng co-authors on Estimates of Global, Regional, and National Morbidity, Mortality, and Aetiologies of Diarrhoeal Diseases: A Systematic Analysis for the Global Burden of Disease Study 2015, 2 June 2017.

There was a large CVD/CVD-Mali presence at the 11th Annual Rotavirus Symposium, Lilongwe, Malawi, 28-30 May 2017.

Monica McArthur, MD, PhD and Marcela Pasetti, PhD, were among coauthors on Human Immune Responses Against Shigella and Enterotoxigenic E. coli: Current Advances and the Path Forward, 27 May 2017.

Myron M. Levine, MD, DTPH, received the National Foundation for Infectious Diseases (NFID) Maxwell Finland Award for Scientific Achievement, 18 May 2017.

Wilbur Chen, MD, MS, was a collaborator on Immune Plasma for the Treatment of Severe Influenza: An Open-label, Multicentre, Phase 2 Randomised Study, 15 May 2017.

Archived News